Dipeptidyl-Peptidase IV Inhibitors
"Dipeptidyl-Peptidase IV Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that suppress the degradation of INCRETINS by blocking the action of DIPEPTIDYL-PEPTIDASE IV. This helps to correct the defective INSULIN and GLUCAGON secretion characteristic of TYPE 2 DIABETES MELLITUS by stimulating insulin secretion and suppressing glucagon release.
Descriptor ID |
D054873
|
MeSH Number(s) |
D27.505.519.389.745.335 D27.505.696.422.500
|
Concept/Terms |
Dipeptidyl-Peptidase IV Inhibitors- Dipeptidyl-Peptidase IV Inhibitors
- Dipeptidyl Peptidase IV Inhibitors
- Inhibitors, Dipeptidyl-Peptidase IV
- Dipeptidyl-Peptidase 4 Inhibitors
- Dipeptidyl Peptidase 4 Inhibitors
- Gliptins
|
Below are MeSH descriptors whose meaning is more general than "Dipeptidyl-Peptidase IV Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Dipeptidyl-Peptidase IV Inhibitors".
This graph shows the total number of publications written about "Dipeptidyl-Peptidase IV Inhibitors" by people in UAMS Profiles by year, and whether "Dipeptidyl-Peptidase IV Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2019 | 1 | 0 | 1 | 2017 | 1 | 0 | 1 | 2016 | 1 | 1 | 2 | 2015 | 1 | 0 | 1 | 2013 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Dipeptidyl-Peptidase IV Inhibitors" by people in Profiles over the past ten years.
-
King J, McAdam-Marx C, McCaleb R, Davis D, Bemberg GB, Johnson JT. Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan. J Manag Care Spec Pharm. 2019 Jun; 25(6):646-651.
-
Uchida T, Wakasugi M, Kitamura T, Yamamoto T, Asakura M, Fujiwara R, Itoh T, Fujii H, Hirono S. Exploration of DPP-IV inhibitors with a novel scaffold by multistep in silico screening. J Mol Graph Model. 2018 01; 79:254-263.
-
Cha SA, Park YM, Yun JS, Lim TS, Song KH, Yoo KD, Ahn YB, Ko SH. A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes. Lipids Health Dis. 2017 Apr 13; 16(1):58.
-
Asakura M, Karaki F, Fujii H, Atsuda K, Itoh T, Fujiwara R. Vildagliptin and its metabolite M20.7 induce the expression of S100A8 and S100A9 in human hepatoma HepG2 and leukemia HL-60 cells. Sci Rep. 2016 10 19; 6:35633.
-
Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, Durand M, Hu N, Juurlink DN, Paterson JM, Targownik LE, Turin TC, Ernst P, Suissa S, Dormuth CR, Hemmelgarn BR, Teare GF, Caetano P, Chateau D, Henry DA, Paterson JM, LeLorier J, Levy AR, Ernst P, Platt RW, Sketris IS. Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis. JAMA Intern Med. 2016 Oct 01; 176(10):1464-1473.
-
Wang X, Ding Z, Yang F, Dai Y, Chen P, Theus S, Singh S, Budhiraja M, Mehta JL. Modulation of myocardial injury and collagen deposition following ischaemia-reperfusion by linagliptin and liraglutide, and both together. Clin Sci (Lond). 2016 08 01; 130(15):1353-62.
-
Yamashita Y, Asakura M, Mitsugi R, Fujii H, Nagai K, Atsuda K, Itoh T, Fujiwara R. MicroRNA expression in the vildagliptin-treated two- and three-dimensional HepG2 cells. Drug Metab Pharmacokinet. 2016 Jun; 31(3):201-9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|